Kornimate/medical-research-clean huggingface dataset:
duration of lower labial segment alignment with repeated micro-osteoperforations:

Conditions: Malocclusion

Summary: the main purpose is to compare overall alignment time (oat) in days in alleviating mandibular incisors crowding between control group and mops group.furthermore, to investigate the presence of volumetric root resorption from cbct, gingival recession and formation of black triangle post lower labial segment alignment between micro-osteoperforations group and control group.

prolonged treatment time in orthodontics is an undesirable side effect for both the patient and clinician. usually, an average course of comprehensive orthodontic treatment with fixed appliances requires less than 2 years to complete (19.9 months). this prolonged treatment time may cause adverse effects such as root resorption, gingival recession, caries \& enamel demineralization. micro-osteoperforations is safe, minimally invasive technique which perforations are performed through the gum tissues, penetrating the bone without the need to raise a ﬂap.control group will not received any mop and will receive standard orthodontic treatment.

Eligibility criteria:
inclusion criteria: * gender : male and female * age range : ≥ 18years to 45 years old * crowding of 3mm - 7mm on lower labial segment (lower right canine to lower left canine) which does not require extractions in the lower arch * class ii div i incisor relationship with extraction of both upper 1st premolars * maximum anchorage control with temporary anchorage device ( tad) , with molar class ii (¼ to full unit) malocclusion * average vertical facial proportions * no systemic disease * acceptable good oral hygiene * no periodontal disease exclusion criteria: * smokers * distally angulated canines * history of trauma (crown fracture or avulsion and re-implantation) , endodontic treatment * missing permanent mandibular anterior teeth ( hypodontia) / retained deciduous teeth in mandibular anterior area * habits eg: fingernails biting , toothpick user , using hard toothbrush * vertical skeletal discrepancies eg high angle and low angle * systemic disease especially on long term use of antibiotics, phenytoin, cyclosporin, anti-inflammatory drugs, systemic corticosteroid and calcium channel blockers * poor oral hygiene for more than 3 visits * current periodontal disease

Keywords: micro-osteperforation orthodontic tooth movement treatment duration
a population-based case-control study of biliary tract cancers in shanghai, china

Conditions: Biliary Tract Cancer

Summary: the key aims of this study include estimation of possible risk associated with a history of gallstones, bacterial infection for the biliary tract, other medical history, diet, use of tobacco and alcohol, obesity, reproductive factors, and family history of cancer. information will be used to examine risk patterns a) seperately by anatomic subsite; b) among patients with gallbladder cancer vs. controls undergoing cholecystectomy for gallstones; c) among the patients with bile duct cancer vs. hospital controls without cancer who undergo surgery for removal of bile duct stones. we will also attempt to ascertain reasons for cancer who undergo surgery for removal of bile duct stones. we will also attempt to ascertain reasons for the rising incidence of biliary tract cancers in shanghai. serum collected from all subjects will be analyzed for estrogens and other hormones, vitamins c and e, cholesterol, and bacterial antibodies (including salmonella typhi, paratyphi, and escherischia coli). bile fluid will be cultured for aerobic bacteria, and gallstones analyzed for color, cholesterol, and evidence of bacteria infection. a major challenge in biliary tract cancer research is to determine how cancer risk factors differ from those for gallstones or biliary duct stone disease, since many people have gallstones (or biliary duct stones) but few develop cancer....

the key aims of this study include estimation of possible risk associated with a history of gallstones, bacterial infection for the biliary tract, other medical history, diet, use of tobacco and alcohol, obesity, reproductive factors, and family history of cancer. information will be used to examine risk patterns a) seperately by anatomic subsite; b) among patients with gallbladder cancer vs. controls undergoing cholecystectomy for gallstones; c) among the patients with bile duct cancer vs. hospital controls without cancer who undergo surgery for removal of bile duct stones. we will also attempt to ascertain reasons for cancer who undergo surgery for removal of bile duct stones. we will also attempt to ascertain reasons for the rising incidence of biliary tract cancers in shanghai. serum collected from all subjects will be analyzed for estrogens and other hormones, vitamins c and e, cholesterol, and bacterial antibodies (including salmonella typhi, paratyphi, and escherischia coli). bile fluid will be cultured for aerobic bacteria, and gallstones analyzed for color, cholesterol, and evidence of bacteria infection. a major challenge in biliary tract cancer research is to determine how cancer risk factors differ from those for gallstones or biliary duct stone disease, since many people have gallstones (or biliary duct stones) but few develop cancer.

Eligibility criteria:
* inclusion criteria: cases of biliary tract cancer newly diagnosed between september 1, 1996 and august 31, 1999 among residents of urban shanghai. must be under the age of 75 at the time of diagnosis.

Keywords: ampulla of vater gallbaldder cancer extrahepatic bile duct
an electronic health record-based approach to increase prep knowledge and uptake: the emc2 prep strategy

Conditions: HIV Infections; Electronic Health Record; Primary Health Care

Summary: this study is being conducted to investigate a strategy that may improve knowledge and uptake of pre-exposure prophylaxis for hiv prevention (prep) among cisgender women in primary care.

members of the study team previously developed and evaluated the electronic health record medication complete communication (emc2) strategy to 'hardwire' provider/patient communication \& surveillance of select prescription (rx) medications. emc2 prep will adapt from the previous strategy to * educate cisgender women in primary care who have increased vulnerability to hiv about prep using an interactive, health literacy-appropriate educational tool securely delivered via the patient portal * facilitate, for those who express interest, the rapid and discrete scheduling of a dedicated prep clinic visit with a primary care clinician trained in prep delivery the current study aims are to: aim 1: refine and implement an electronic health record (ehr)-based strategy as a potential quality improvement activity that supports informed decision-making and prep uptake among women with increased hiv vulnerability in primary care (the emc2 prep strategy). aim 2: pilot-test the emc2 prep strategy in primary care to determine its feasibility, acceptability, and preliminary efficacy among women with increased vulnerability to hiv. aim 3: develop a standard operating protocol (sop) for disseminating the emc2 prep strategy to a national network of federally qualified health centers.

Eligibility criteria:
inclusion criteria: * female * hiv negative * have received 2 or more tests in the past 12 months for chlamydia, gonorrhea and/or syphilis * and/or have received a positive diagnosis for at least one of those sexually transmitted infections in the past 6 months * currently engaged in primary care * not currently using prep exclusion criteria: * severe, uncorrectable visual, hearing or cognitive impairments that would preclude study consent or participation
a study of roactemra/actemra (tocilizumab) in patients with active systemic juvenile idiopathic arthritis (jia)

Conditions: Juvenile Idiopathic Arthritis

Summary: this study will evaluate the efficacy and safety of roactemra/actemra (tocilizumab) in patients with active systemic juvenile idiopathic arthritis (sjia) who have an inadequate clinical response to nsaids and corticosteroids. in part i of the study patients will be randomized 2:1 to receive iv infusions of roactemra/actemra (8mg/kg iv for patients \>=30kg, or 12mg/kg for patients \<30kg) or placebo, every 2 weeks. stable nsaids and methotrexate will be continued throughout. after 12 weeks of double-blind treatment, all patients will have the option to enter part ii of the study to receive open-label treatment with roactemra/actemra for a further 92 weeks, followed by a 3-year continuation of the study in part iii in which, for patients who meet specific criteria, an optional alternative dosing schedule decreasing the study drug administration frequency will be introduced. anticipated time on study treatment is up to 5 years.


Eligibility criteria:
inclusion criteria: * patients aged 2-17 years of age * systemic juvenile idiopathic arthritis with \>= 6 months persistent activity * presence of active disease (\>=5 active joints, or \>=2 active joints + fever + steroids) * inadequate clinical response to nonsteroidal anti-inflammatory drugs (nsaids) and corticosteroids due to toxicity or lack of efficacy exclusion criteria: * wheelchair-bound or bed-ridden * any other autoimmune, rheumatic disease or overlap syndrome other than systemic juvenile idiopathic arthritis * intravenous long-acting corticosteroids or intra-articular corticosteroids within 4 weeks of baseline, or throughout study * disease-modifying antirheumatic drugs (dmards), other than methotrexate * previous treatment with tocilizumab
prostatic artery embolization for benign prostatic hyperplasia

Conditions: Benign Prostate Hyperplasia

Summary: to evaluate whether prostatic artery embolization (pae) might be an effective alternative treatment option for benign prostatic hyperplasia (bph), in comparison to current gold standard surgical treatment- transurethral resection of prostate (turp).


Eligibility criteria:
inclusion criteria: 1. moderate to severe lower urinary tract symptoms (i.e. international prostate symptom score ipss\>8) who are bothered by their symptoms (i.e., interfere with the daily activities of living) 2. urinary retention (related to bph) leading to catheterization. 3. refractory to medical treatment or patient is not willing to consider medical treatment 4. pre trans-urethral resection of prostate (turp) to reduce the size of prostate gland if prostate is too big for turp surgery. exclusion criteria: 1. mild symptoms (ipss \<8) 2. moderate to severe lower urinary tract symptoms (i.e. ipss\>8) who are not bothered by their symptoms (i.e., symptoms do not interfere with the daily activities of living). 3. suspected malignancy. 4. any of the following clearly related to bph- bladder stones, recurrent utis, and renal insufficiency. 5. advanced atherosclerosis and unsuitable vascular access. 6. allergy to intravenous contra

Keywords: bph
child-physician recommendation on parental adherence to colorectal cancer screening

Conditions: Colorectal Cancer

Summary: physician recommendation has been shown to be one of the most significant predictors for colorectal cancer (crc) screening. this study aims to identify the amount of parents of internal medicine residents at nyu who are eligible for crc screening but have not received it. investigators will perform an intervention and quantify the amount of parents eligible for crc screening after the intervention. this study will entail sending 2 brief surveys (one before the intervention and one after) which determine if the parents of the residents are eligible for crc screening. the intervention will be asking the residents with eligible parents to have a discussion with their parents about crc screening options and to address their concerns. investigators will provide a one page document the residents can give their parents as a reference as part of the intervention.


Eligibility criteria:
inclusion criteria: * internal medicine residents at nyu - pgy1, pgy2, and pgy3 during 2017-2018 academic year
the efficacy and safety of peg-rhg-csf in preventing chemotherapy-induced neutropenia

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of peg-rhg-csf in preventing chemotherapy-induced neutropenia

neutrophilic granulocytopenias is one of the most common and most serious complications in chemotherapy. research shows that about 25% \~ 40% in patients receiving standard chemotherapy can appear neutropenia with fever. it can increase the risk of infection and chemotherapy related death, and lead to the delay of chemotherapy, and maybe reduce the curative effect of chemotherapy. rhg-csf has widely used to prevent neutropenia, but its half-time is short, and need daily injections to maintain the effective blood drug concentration. patients are with poor compliance, related adverse reaction and medical costs increase. at the same time, some patients appear neutropenia thought rhg-csf is given. therefore, how to reduce the frequency of rhg-csf injections and more effectively prevent neutropenia more effectively, on the premise of ensure the safety of patients to achieve better effect of chemotherapy, has always been the focus of the clinical problem. pegylated recombinant human granulocyte-colony stimulating factor(peg-rhg-csf) is a first class national new drug developed by domestic pharmaceutical companies. according to some phase ⅱand phase ⅲ clinical trials, peg-rhg-csf has a good effect. the patients need only one injection for peg-rhg-csf each cycle of chemotherapy, and the effect of rising white blood cell is more smoothly, and it can avoid pain of repeated injection of peg-rhg-csf

Eligibility criteria:
inclusion criteria: 1. provision of informed consent histologically proven breast cancer 2. patients need to accept many cycles chemotherapy alone 3. appears iii/iv neutropenia after last cycle of chemotherapy, and plan in the subsequent cycle using the same chemotherapy program. 4. kps≥70 5. lifetime is expected to more than 3 months 6. before enrollment,anc≥anc ≥1.5×109 /l,platelet count (plt) ≥80×109 /l, white blood cell （wbc ）≥3.0×109 /l. 7. sign informed consent form （icf）. exclusion criteria: 1. there is any difficult to control infection, or within 72 h before chemotherapy received antibiotic treatment systematically 2. any abnormal bone marrow hyperplasia and other hematopoietic function was abnormal 3. suffer from other malignant tumor was not cured, or patients with brain metastasis 4. total bilirubin （tbil）,alanine transminase （alt）,aspartate aminotransferase(ast)\>2.5×uln 5. cr\>1.5×uln 6. be allergic to this product or other genetically engineered e. coli sources of biological products 7. mental or neurological disorders 8. women with pregnancy or lactation; the childbearing age women refused to accept contraception 9. the investigators think that the person doesn't fit into the group
study to assess the efficacy of larazotide acetate for the treatment of celiac disease

Conditions: Celiac Disease

Summary: this study was conducted to evaluate the efficacy of multiple doses of larazotide acetate in preventing intestinal permeability changes induced by a 6- week gluten challenge in subjects with celiac disease.

this was a phase iib, randomized, double-blind, placebo-controlled, dose ranging, multicenter study to determine the safety, tolerance, and efficacy of larazotide acetate in subjects with celiac disease during a gluten challenge. subjects remained on their gluten-free diet throughout the duration of the trial. study drug or drug placebo capsules were administered tid 15 minutes before each meal. gluten or gluten placebo capsules will be taken tid with each meal.

Eligibility criteria:
inclusion criteria: * male and female adults with biopsy proven celiac disease on a gluten-free diet for at least the past 6 months * anti-tissue transglutaminase (anti-ttg) ≤ 10 eu. * bmi between 18.5 and 38, inclusive. exclusion criteria * has chronic active gi disease other than celiac disease * has diabetes (type 1 or type 2). * unable to abstain from alcohol consumption or nsaid use for 48 hours prior to each intestinal permeability collection throughout the study. * has hemoglobin value below 8.5 g/dl

Keywords: larazotide acetate
gene expression in pregnancies complicated by preeclampsia

Conditions: Preeclampsia

Summary: the purpose of this study is to figure out some of the differences in bodily function between women who have preeclampsia and those who do not. * this may eventually lead to an understanding of its cause. at this time, there is no known way to prevent preeclampsia, and the cause is not known. * the only treatment is delivery of the baby, even if it is premature, in order to decrease the risk to the mother.

* preeclampsia is a pregnancy-related disorder that occurs in about 6% of all pregnancies. * in its mild for, preeclampsia involves high blood pressure. more severe forms of preeclampsia can lead to more serious pregnancy complications. * at this time, there is no known way to prevent preeclampsia, and the cause is not known. the only treatment is delivery of the baby, even if it is premature, in order to decrease the risk to the mother. * the purpose of this study is to figure out some of the differences in bodily function between women who have preeclampsia and those who do not. this may eventually lead to an understanding of its cause.

Eligibility criteria:
inclusion criteria: * gravidas at 32-42 weeks gestation,who have preeclampsia as defined by sibai et al, 1997. * control patients: gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, maternal age, and race. exclusion criteria: * prior betamethasone administration, fetal growth restriction (\<3%ile), prior chronic hypertension (nonpregnant or \< 20 weeks gestation any pregnancy), chorioamnionitis, major fetal anomaly or chromosome abnormality, multiple gestation, and maternal diabetes (any class except diet-controlled gestational).
diagnostic study of quantitative imaging and spectroscopy in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: objectives: i. determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, t2 and enhanced t1 lesion volume, and the magnetization transfer ratio histogram parameters, and correlate these measurements with clinical measures of disability in patients with multiple sclerosis. ii. measure the quantity of whole brain n-acetylaspartate in patients with multiple sclerosis and compare these values to those from age matched controls. iii. determine the correlation between specific neuropsychological tests which assess global cognitive functioning and the quantitative measurements taken in these patients in this study.

protocol outline: patients undergo magnetic resonance imaging and spectroscopy with standard gadolinium contrast followed by neuropsychological testing every 6 months for 5 years. an equal number of age and sex matched healthy patients act as a control group and undergo magnetic resonance imaging and spectroscopy without standard gadolinium contrast every 6 months for 5 years.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnosis of multiple sclerosis relapsing-remitting defined as 2 exacerbations and a worsening of neurologic function over 1 day followed by at least 30 days of no progression or secondary-progressive defined as increase of at least 1.0 unit on expanded disability status scale (edss) in past 2 years with or without exacerbations --prior/concurrent therapy-- * biologic therapy: prior interferon beta 1a, 1b, or glatiramer acetate no concurrent interferon beta 1a, 1b, or glatiramer acetate * endocrine therapy: concurrent oral and iv corticosteroids allowed --patient characteristics-- * performance status: edss no greater than 7.0 * hematopoietic: no hematologic dysfunction including hemolytic anemia * hepatic: no hepatic dysfunction * renal: no renal dysfunction * cardiovascular: no cardiac pacemaker * other: not pregnant or nursing negative pregnancy test no intracranial clips, metal implants, or external clips within 10 mm of head no metal in eyes no known gadolinium texaphyrin allergy no known claustrophobia

Keywords: multiple sclerosis neurologic and psychiatric disorders rare disease
corifollitropin alfa followed by hphmg in a long gnrh agonist protocol for the treatment of poor ovarian responders

Conditions: Infertility; Poor Ovarian Response

Summary: the purpose of the present study is to examine the level of ovarian response and the pregnancy rates among poor ovarian responders treated with a novel treatment protocol with 150μg corifollitropin alfa followed by 300iu hmg in a long gnrh agonist protocol.

corifollitropin alfa reaches maximum concentrations (cmax), between 25 and 45 h after injection , a time interval which is significantly shorter as compared to treatment with rfsh. the investigators hypothesized that this rapid increase in the serum fsh concentration may result in a significantly higher exposure of the small antral follicles to constant high levels of fsh during the early follicular phase, securing not only the recruitment of the follicles, but also the continued growth. in the current study the investigators examine whether administration of corifollitropin followed by 300iu hmg in a long gnrh agonist protocol may result in acceptable pregnancy rates in poor ovarian responders fulfilling the "bologna criteria"

Eligibility criteria:
inclusion criteria: patients should fulfill the "bologna criteria" for poor ovarian response at least two of the following three features must be present: i. advanced maternal age (≥40 years) or any other risk factor for por (poor ovarian response); ii. a previous por (≤3 oocytes with a conventional stimulation protocol); iii. an abnormal ovarian reserve test (i.e. afc \<7 follicles or amh \<1.1 ng/ml). two episodes of por after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ort (ovarian reserve test). exclusion criteria: -

Keywords: poor ovarian response poor ovarian responders bologna criteria for poor ovarian response
follow-up study to evaluate the safety and efficacy of fcn-159 in pediatric participants with neurofibromatosis type 1

Conditions: Neurofibromatosis 1; Plexiform Neurofibroma; NF1

Summary: fcn-159 (luvometinib tablets), an orally available and highly potent selective inhibitor of mek1/2,demonstrated good tolerability and exhibited notable anti-tumor activity in pediatric pts with nf1-related pn in study nct04954001.this study is a 5-year long-term follow-up of the fcn-159-002 study, involving all enrolled patients to further assess safety, growth and development effects, and treatment efficacy.


Eligibility criteria:
inclusion criteria: patients from the pediatric cohort of the fcn-159-002 study. willing to participate in the long-term follow-up study and capable of understanding and voluntarily signing the informed consent form. exclusion criteria: any clinically significant condition that, in the investigator's judgment, may interfere with study participation or compliance with safety requirements. patients unable to comply with visit-related requirements.